• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap™ PKB/Akt Inhibitor (Oncology)
        • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Search
  • Menu Menu
You are here: Home1 / 20092 / Astex reports positive data from its Phase I study of AT9283 at the ASCO...

Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009

16 May 2009/in 2009, News

Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2009-05-16 12:39:392016-11-28 12:40:02Astex reports positive data from its Phase I study of AT9283 at the ASCO Annual Meeting 2009

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

SuperGen’s MP-470 Demonstrates Clinical Benefit in Lung Cancer Patien...SuperGen Names Mohammad Azab, M.D., Chief Medical Officer
Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok